BEGIN:VCALENDAR VERSION:2.0 PRODID:-//wp-events-plugin.com//7.2.3.1//EN TZID:America/New_York X-WR-TIMEZONE:America/New_York BEGIN:VEVENT UID:140@fibrofoundation.org DTSTART;TZID=America/New_York:20230223T200000 DTEND;TZID=America/New_York:20230223T210000 DTSTAMP:20230224T204351Z URL:https://fibrofoundation.org/events/precision-therapies-for-rare-cancer sssion-prognosis/ SUMMARY:Precision Therapies for Rare Cancers DESCRIPTION:This webinar is the final webinar in which we explore how preci sion cancer medicine is being applied to rare cancers.\n\nPrecision medici ne looks at the genetic and molecular characteristics of a patient’s uni que tumor to identify the tumor’s specific weaknesses. Once that level o f identification is possible\, custom-selected treatments that attack thos e specific vulnerabilities have great potential to improve patient outcome s.\n\nPlease join us as Mark Furth\, Scientific Director of the Fibrolamel lar Cancer Foundation\, leads a group of distinguished panelists in a disc ussion of the science and challenges behind the development of different t ypes of targeted therapy and immunotherapy. Key topics and issues to be ex plored in this webinar include:\n\n Current landscape &\; challenges\n Targeted drugs for “challenging” targets\n\n Protein kinases\n Tra nscription factors\n Fusion proteins\n\n\n Advanced drug discovery\n\n Structure-based drug design\n Monoclonal antibodies &\; antibody-drug conjugates\n Inhibitory RNAs\n Protein degraders\n Gene targeting\n Im mune therapies\n\n Vaccines\n Cell therapy\n\n\n\n\n\nPanelists:\n\n Na beel Bardeesy\, PhD – Dr.  Bardeesy received his PhD in Biochemistry fr om McGill University and completed a Postdoctoral Fellowship at the Dana-F arber Cancer Institute at Harvard University. Dr. Bardeesy has led his own laboratory at the MGH Cancer Center since 2005. His research concentrates on liver\, biliary\, and pancreatic cancers. Dr. Bardeesy is a leading ex pert in cancers driven by alterations in protein kinase A (PKA) signaling pathways. His laboratory develops mouse and human models of cancers and ut ilizes them to develop targeted therapies tailored to tumors’ genetic ma keup.\n Razelle Kurzrock\, MD – Dr. Kurzrock has extensive experience i n personalized cancer therapy and innovative clinical trials. She has publ ished almost 900 peer-reviewed articles in elite medical journals\, and sh e has been the Principal Investigator (PI) of numerous grants and funding awards totaling over $100 million. Dr. Kurzrock has a special passion to s tudy and treat Rare Cancers. She founded a Rare Tumor Clinic at UCSD\, hea ds the Early Therapeutics and Rare Cancers Committee for the NCI cooperati ve group SWOG\, and has founded a Precision Medicine and Rare Cancers Clin ic at the Medical College of Wisconsin (MCW).\n John Scott\, PhD – Dr. Scott is the Edwin G. Krebs – Speights Professor of Cell Signaling and C ancer Biology and the Chairman of the Department of Pharmacology at the Un iversity of Washington School of Medicine. He is a member of the Medical a nd Scientific Advisory Board of the Fibrolamellar Cancer Foundation. Dr. S cott has done pioneering research on understanding cellular signaling and the discovery of drugs that modulate that signalling since his postdoctora l studies with Nobel laureate Edwin Krebs. He has deep expertise in the re gulation of protein kinases and phosphatases\, enzymes that are central to the control of cellular metabolism and division. Much of his work focuses on the organization of intracellular “signaling islands” that ensure the efficient and accurate response of cells to environmental cues and how that organization is changed within cancerous cells.\n\nVideo of the even t:\n\nPlease visit FCF's YouTube channel to view a recording of the event. CATEGORIES:FCF event END:VEVENT BEGIN:VTIMEZONE TZID:America/New_York X-LIC-LOCATION:America/New_York BEGIN:STANDARD DTSTART:20221106T010000 TZOFFSETFROM:-0400 TZOFFSETTO:-0500 TZNAME:EST END:STANDARD END:VTIMEZONE END:VCALENDAR